Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predictive factors for enzalutamide response in castration-resistant prostate cancer
jRCTs051180140Completed
- Sponsor
- Astellas Pharma
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of enzalutamide in castration-resistant prostate cancer (CRPC) (3 arms), sponsored by Astellas Pharma. Primary endpoints: Association between genetic profile of castration-resistant prostate cancer tissue and sensitivity to enzalutamide, Association between newly acquired genetic aberrations during development of castration resistance and sensitivity to enzalutamide and 1 more. Started Mar 2016; status: completed.
02
Drugs
enzalutamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on jRCTs051180140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180140.